UK leaders: Takeda’s Jon Neal

In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a

Hormonal drug shortages in UK ‘harming women’, say doctors

Woodford biotech ‘fire-sale’ looms after rescue bid fails; r...

Future prospects for an Innovative Medicines Fund for Englan...

On the 12 December 2019, the UK general public voted for a further five years of Conservative government.

An alternative set of metrics for the UK’s pricing and acces...

Leela Barham takes a look at alternative ways pharma and the UK government could measure progress for the VPAS.

Future proofing the UK’s research ecosystem in the face of g...

The UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits that come with it – in the face of global change requires adaptation.